# Preoperative Use of Liraglutide Additionally to Common Dietological Measures as Opposed to Dietological Measures Alone

> **NCT06865365** · PHASE4 · NOT_YET_RECRUITING · sponsor: **Medical University of Vienna** · enrollment: 72 (estimated)

## Conditions studied

- Obesity, Adolescent

## Interventions

- **DRUG:** Liraglutide daily (0.6-3.0mg, highest tolerable dose) additional to dietological measures and lifestyle optimization suggestions
- **BEHAVIORAL:** Dietologic measures and lifestyle optimization for weight loss

## Key facts

- **NCT ID:** NCT06865365
- **Lead sponsor:** Medical University of Vienna
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-05-01
- **Primary completion:** 2027-02-01
- **Final completion:** 2028-02-01
- **Target enrollment:** 72 (ESTIMATED)
- **Last updated:** 2025-03-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06865365

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06865365, "Preoperative Use of Liraglutide Additionally to Common Dietological Measures as Opposed to Dietological Measures Alone". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06865365. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*